GRIFF/SMC WINS BEST CREATIVE, BEST STRATEGY AND TWO GOLD KEY AWARDS FROM BUSINESS MARKETING ASSOCIATION. 

LONGMONT, CO May 7th, 2012. Acertara Acoustic Laboratories, the world’s only independent ISO/IEC 17025:2005 accredited medical ultrasound acoustic measurement and testing laboratory, announces that its research and development team has been awarded three new United States patents in as many weeks. US patents 8,159,900, 8,164,976, and 8,169,853, authored by John Timms, James Gessert, Matthew Fitzgibbons, and G. Wayne Moore are related to novel technology designed to validate the performance of diagnostic ultrasound systems. The R&D team members of Acertara have been awarded more than 30 United States patents. 

The Innovation Center of the Rockies (formerly the Boulder Innovation Center) has entered into a commercialization partnership with CSU Ventures to accelerate the creation of new businesses based on CSU faculty research. The ICR will work with CSU Ventures staff to develop the intellectual properties holding the most promise for commercialization within a variety of markets supported by ICR including Bioscience, Cleantech, Engineering, Aerospace and IT/Software.  Full story 
  

May 3, 2012 — In support of its strategic partnership with cloud computing provider NetSuite and the growing demand from clients, Hein & Associates’ Business Advisory Services group has added three experienced Managers to its NetSuite Implementation Services team:  Michael Dooley, Jeremy King, and Todd Lindley. 

CENTENNIAL, Colo., May 2, 2012 /PRNewswire/ -- Cochlear Americas, the world's leading implantable hearing solutions company, announced today the launch of its smartphone support application for Nucleus® Cochlear Implant recipients. The Nucleus Support App joins the Baha® Support App as part of Cochlear's mobile support initiative, which provides information and assistance to recipients whenever and wherever they need it. 

INDUSTRY VETERAN BRINGS SALES EXPERTISE TO ALLOSOURCE’S GROWING DISTRIBUTION NETWORK 

BOULDER, CO, April 26, 2012 – MiRagen Therapeutics, Inc., a biopharmaceutical company developing innovative microRNA (miRNA)-based therapeutics primarily for the treatment of patients who suffer from cardiovascular and muscle disease, announced today that scientific results published in the journal Cell reveal the central role of the heart in whole-body metabolism.   

Today, the Obama Administration announced its commitment to strengthening bioscience research as a major driver of American innovation and economic growth.  The National Bioeconomy Blueprint outlines steps that agencies will take to drive the bioeconomy—economic activity powered by research and innovation in the biosciences—and details ongoing efforts across the Federal government to realize this goal.